“…44,45,53,54 In this review, researchers reported a risk of recurrence after DTaP ±Hib/ HepB/IPV and DTwP vaccines of <0.8% in all the studies that included patients with HHE. 5,29,31,32 However, the risk of recurrence after DTwP combined with Hib, injectable poliomyelitis, or HepB antigens, which is currently used in low-and middle-income countries, was not evaluated.…”